View all newsletters
Receive our newsletter - data, insights and analysis delivered to you

Three Out of Every Four Covid-19 Vaccine Projects Across the Globe Rely on SCHOTT Vials

Last year, SCHOTT declared an investment of $1bn in its pharmaceutical packaging business to increase capacity by more than 50%.

SCHOTT has now achieved a milestone, delivering vials to three out of every four Covid-19 vaccine projects undergoing phase I, II, and III testing. Already, the company has delivered millions of glass vials to SARS-CoV-2 programs including partners of Operation Warp Speed in the US.

“We are proud and happy to serve leading vaccine projects and will continue to contribute our utmost to the fight against Covid-19,” said Frank Heinricht, CEO of SCHOTT AG.

The company already deploys a global validated production network with 20 plants and over 600 production lines for pharma glass and packaging and stands ready to supply the industry. “Our $1 billion investment, which started before the pandemic to meet global demand for high-quality glass packaging, allowed us to ramp up production to quickly address this unprecedented global public health challenge,” Heinricht continued.

The vast majority of all Covid-19 vaccines will be stored in and applied from a Borosilicate glass container – the world’s most widely used material to package vaccines. Relying on existing and proven infrastructures and materials enable the pharma industry to save time, simply because they have been processing these vials on their lines for decades.

SCHOTT is a leading international technology group in the areas of speciality glass, glass-ceramics and related high-tech materials. With over 130 years of experience, the company is an innovative partner to many industries, including the home appliance, pharma, electronics, optics, life sciences, automotive and aviation industries. SCHOTT has a global presence with production sites and sales offices in 34 countries. In the 2018/2019 fiscal year, the group generated sales of around $2.54 billion with over 16,200 employees.

For more information, please fill out the enquiry form attached to this page.

The recent spike in market recalls for injectable drug products due to visible flaky particles associated with 'glass delamination' demonstrates the need to solve these...
Protecting medication from undesired interactions with the surrounding environment and preserving their efficacy during shelf life is one of the most pressing challenges for the...
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology